Condition: Chronic Inflammatory Demyelinating Polyneuropathy · Sponsor: Immunovant Sciences GmbH
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
This description comes directly from the study's public registry record.
Study Contact · 18007970414 · clinicaltrials@immunovant.com
Always discuss trial participation with your own doctor first.
| Site Number - 1612 | Tucson, Arizona, United States | Recruiting |
| Site Number - 1618 | Carlsbad, California, United States | Recruiting |
| Site Number - 1619 | Orange, California, United States | Recruiting |
| Site Number - 1607 | Rancho Mirage, California, United States | Recruiting |
| Site Number -1608 | San Francisco, California, United States | Recruiting |
| Site Number - 1626 | Parker, Colorado, United States | Recruiting |
| Site Number - 1621 | New Haven, Connecticut, United States | Recruiting |
| Site Number - 1630 | Washington D.C., District of Columbia, United States | Recruiting |
| Site Number - 1601 | Washington D.C., District of Columbia, United States | Recruiting |
| Site Number - 1603 | Maitland, Florida, United States | Recruiting |
| Site Number - 1606 | Miami, Florida, United States | Recruiting |
| Site Number - 1617 | Ormond Beach, Florida, United States | Recruiting |
+ 126 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07032662